MARKET

ARTL

ARTL

Artelo Biosciences Inc
NASDAQ
1.000
-0.020
-1.96%
Closed 16:00 05/12 EDT
OPEN
1.010
PREV CLOSE
1.020
HIGH
1.040
LOW
1.000
VOLUME
6.81K
TURNOVER
--
52 WEEK HIGH
1.590
52 WEEK LOW
0.8196
MARKET CAP
3.28M
P/E (TTM)
-0.3280
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARTL last week (0505-0509)?
Weekly Report · 11h ago
Weekly Report: what happened at ARTL last week (0428-0502)?
Weekly Report · 05/05 10:50
Artelo Biosciences Receives Nasdaq Non-Compliance Notice
Benzinga · 04/29 20:17
Artelo Biosciences Is Maintained at Buy by D. Boral Capital
Dow Jones · 04/28 14:55
Artelo Biosciences Price Target Maintained With a $6.00/Share by D. Boral Capital
Dow Jones · 04/28 14:55
D. Boral Capital Maintains Buy on Artelo Biosciences, Maintains $6 Price Target
Benzinga · 04/28 14:44
Artelo Biosciences announces publication of peer-reviewed research on ART26.12
TipRanks · 04/28 12:48
Artelo Biosciences Announces Publication Of New Peer-Reviewed Research In "Journal of Investigative Dermatology" Demonstrating ART26.12's Effectiveness In Treating Psoriasis Titled "ART26.12, A FATTY ACID-BINDING PROTEIN 5 INHIBITOR, SHOWS EFFICACY IN PRECLINICAL PSORIASIS MODELS"
Benzinga · 04/28 12:46
More
About ARTL
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

Webull offers Artelo Biosciences Inc stock information, including NASDAQ: ARTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARTL stock methods without spending real money on the virtual paper trading platform.